The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 03, 2021
Filed:
May. 27, 2016
Applicant:
Bristol-myers Squibb Company, Princeton, NJ (US);
Inventors:
Jason Samuel Simon, Westfield, NJ (US);
Petra B. Ross-Macdonald, Pennington, NJ (US);
Assignee:
Bristol-Myers Squibb Company, Princeton, NJ (US);
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); G01N 33/53 (2006.01); C12Q 1/6886 (2018.01); C07K 14/705 (2006.01); A61P 31/00 (2006.01); A61P 1/00 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 39/39533 (2013.01); A61K 39/39558 (2013.01); A61P 1/00 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); C07K 14/7056 (2013.01); C07K 14/70503 (2013.01); C07K 14/70521 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01); Y02A 50/30 (2018.01);
Abstract
This disclosure provides methods for treating a subject afflicted with a tumor derived from a renal cell carcinoma. The methods comprise administering a first dose to a subject of an anti-PD-1 antibody or antigen-binding portion thereof and/or an anti-PD-L1 antibody or antigen-binding portion thereof, and administering a second dose to the subject, wherein the subject exhibited differential expression in one or more biomarker genes, e.g., CTLA-4, TIGIT, and/or PD-L2, following administration of the first dose.